Sareum Share Discussion Threads

[norma_stitts] 21/7/2022 09:36

Gekko202320 Jul '22 - 21:29 - 11528 of 11529 (Filtered)

0 0 0
Gekko202321 Jul '22 - 09:17 - 11529 of 11529 (Filtered)

0 0 0

[gekko2023] 21/7/2022 09:17

Great start...more of this please...x

[gekko2023] 20/7/2022 21:29

Maybe that tweet about the moon landing was actually a secret message after all...

[criticalthinker1] 20/7/2022 21:07

Goodness me! HBD finds someone else's groundwork and he is lauded.
He is imo very close to the board of directors.
He was the one that I mentioned before that had a post that should have just been for the BOD.
Looks like they have seen information made public here that can't be ignored and the share price will react accordingly.
Best regards Steadydanny
Coastal walk tomorrow. Set of at 630am.
Cheese and tomato sandwich prepped and a cheeky lemon drizzle slice the missus made.
Expect this up 8% by 12am.

[criticalthinker1] 20/7/2022 19:58

Don't forget one of our scientific advisors (ex UOL!) Bob Jackson..who else has links at UOL...and if our board/advisors and links to GSK was pharma bingo I'd have a full house!!
CYC116
NTC00560716
This was updated in dec2021.
FLT3
My goodness how many pipeline drugs got updated pre the GSK takeover with patents etc...that have a link to sareum.
Ducks in a row I believe.
Before I was ousted from lse...If by chance sog wip mafuta rmm lazarus read this I would appreciate your opinion that in my opinion there are more wheels within wheels that the board can not report on despite the code agreement last August.
Regards Steadydanny

[gekko2023] 20/7/2022 18:50

This is it..
The month of the rerate...
Many Happy returns...

[criticalthinker1] 20/7/2022 18:04

Great tick up today.

Appreciate some decent individuals are aware of some posts re SIERRA ONCOLOGY and 737 that go back to last year and finds on here that proved 737 has not been on hold,albeit told by some it was of no consequence.

Good enough for me.

PS those who actually are genuine investors here I'd add as a point of possible research that Haleon is imo underpriced by 35% minimum and GSK will continue to rise.

The split was not a whim to satisfy Elliot. Absolute full respect to Emma and she has a few pipelines re GSK that will garner further gain.

And Unilever offered 50 billion for the pre Haleon opportunity. GSK turned it down!

As always dyor etc.

Best regards Steadydanny

[gekko2023] 20/7/2022 15:00

As I write this...SAR sits at 200p and 6.67% up on the day. What's happening?! Dyor

[gekko2023] 20/7/2022 14:59

This is a 5x bagger.. 20p a share...c.£1 target value...its going to the moon...xxx

[horridhenry] 20/7/2022 12:30

CHAR - let me guess, you are down, having invested near the top in April 22, and you want to get out, just like this one eh Gekko

[horridhenry] 20/7/2022 12:02

even the board fool who knows very little commented that your view and posting style is changing

[horridhenry] 20/7/2022 11:56

gekko, very tricky to make out exactly what you are up to
Your posting is very different now to when you first appeared
Is the stress caused by losing too much for you ?

[horridhenry] 20/7/2022 11:41

i wouldn't want to meet you, we have one like you in our local pub, and he is ignored by anyone who knows him, and is regularly punched by people that don't.

If i ignore you then you will carry on trying to mislead new investor's into thinking you know what you are talking about, and someone (god forbid) invests on that basis

[criticalthinker1] 20/7/2022 11:25

Henry just fo you imbecile.

I would love to meet you.

[horridhenry] 20/7/2022 10:31

CHAR - nonsense tip from an idiot with zero credibility

You slag this off then go and make a fool of yourself

keep it up laddy

[gekko2023] 20/7/2022 07:22

Fellow Sareumites...check out Chariot Oil and Gas today...RNS shows massive recoverable gas reserves...atva time when the Ruskies are threatening to turn off gas supplies...this IS a business with newsflow that can deliver a timely need...check it out...20p a share...Cenkos target 60p a share...Gekko...xx

[criticalthinker1] 19/7/2022 22:07

Corporate governance
Last updated 27 August 2021

Introduction
The new Quoted Companies Alliance Corporate Governance Code (QCA Code) makes clear it is the prime responsibility of the Chairman to ensure the Company applies the QCA Code to best advantage of all stakeholders.

Sareum Holdings plc is an established operation with a clear business model and growth strategy. Our objective is to deliver targeted small molecule therapeutics to treat cancer and autoimmune disease. We seek to build value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage. Applying the appropriate corporate governance practices can only help achieve our goals.

A requirement of the Code is to highlight any areas where we are not in compliance and to provide our reasons why not.

An area of non-compliance is that Dr Stephen Parker, Non-executive Chairman, Dr Michael Owen, Non-executive Director and Mr Clive Birch, Non-executive Director are beneficiaries under the Company’s share option scheme.

Participation by non-executive directors in share based incentive arrangements, while against the provisions of the Code, is common for companies with shares quoted on AIM. Stephen, Michael and Clive provide the Company with a wealth of industry and corporate finance experience. Their participation in the share option scheme provides them with upside at no cash cost to the Company as the value of the Company increases.

The arrangement suits the Company and non-executive directors and we do not currently intend to amend this arrangement.

We trust that the result of our efforts to date provide stakeholders with access to the information they need and the confidence that the Board hold corporate governance compliance in the highest regard.

Dr Stephen Parker
Non-executive Chairman

Well that is food for thought!

Just waiting for that RNS that raises this company to the moon.

Note for Tim. We all heard the squeaky chair during q and a. Go on chap give us a clue or are you bound by ndas?

[gekko2023] 19/7/2022 21:42

Guaranteed...if GSK hands back 737...given the level of hope and expectation attached to that...then the share and sareum are finished....xxx

[horridhenry] 19/7/2022 21:34

Or hand back 737
Just as likely

[criticalthinker1] 19/7/2022 20:57

Mon, 4th Jul 2022 11:23
Sareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - Notes that GSK PLC has completed its acquisition of Sierra Oncology Inc, the licence holder of SRA737, for USD1.9 billion. SRA737 was discovered and initially developed by scientists at the Institute of Cancer Research in collaboration with Sareum.

GSK now owns the licence rights to SRA737, the clinical-stage oral, selective checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.

Under a USD299 million licensing deal between Sierra and CRT Pioneer Fund LP, Sareum was eligible to receive a 27.5% share of any future milestone payments as well as royalties on any future sales of SRA737. The dosing of the first patient with SRA737 in any new clinical trial would result in a USD2.0m payment from Sierra, now GSK, with 27.5% of this due to Sareum.

Just waiting for GSK to mention their focus on DDR.